公开(公告)号：US20200345227A1

公开(公告)日：2020-11-05

申请号：US16935055

申请日：2020-07-21

Applicant: GENENTECH, INC.

Inventor： Michael Bartlett ,  Yi-Zhong Wang

IPC: A61B3/032 ,  A61B3/00 ,  A61B3/11

Abstract: A method to self-test vision of a user for use with a handheld vision tester includes receiving image data of the user's face, determining dimensions of the user's face based on the received image data, computing a user viewing distance based on the determined dimensions, displaying a vision test based on the computed user viewing distance, receiving user input responses to the vision test, and outputting results of the vision test from the user input responses.

公开(公告)号：US10808028B2

公开(公告)日：2020-10-20

申请号：US16021248

申请日：2018-06-28

Applicant: Genentech, Inc.

Inventor： Robert F. Kelley ,  Marissa L. Matsumoto

IPC: A61K39/00 ,  C07K16/18 ,  G01N33/68 ,  C07K14/47

Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.

公开(公告)号：US20200325538A1

公开(公告)日：2020-10-15

申请号：US16845575

申请日：2020-04-10

Applicant: GENENTECH, INC.

Inventor： Jason A. Hackney ,  Mary Keir ,  Gaik Wei Tew

IPC: C12Q1/6883 ,  C07K16/28

Abstract: Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

公开(公告)号：US20200325187A1

公开(公告)日：2020-10-15

申请号：US16915387

申请日：2020-06-29

Applicant: Genentech, Inc.

Inventor： Rami HANNOUSH ,  Harini KALUARACHCHI ,  Aaron NILE ,  Cameron NOLAND ,  Yingnan ZHANG ,  Lijuan ZHOU ,  Xinxin GAO

IPC: C07K14/415 ,  A61K38/00 ,  C07K14/81 ,  C07K14/47 ,  A61K9/50 ,  A61K9/00 ,  A61K38/16 ,  A61K47/34 ,  C07K14/00

Abstract: Provided are non-naturally occurring cystine knot peptides (CKPs) that bind to VEGF-A. Additionally, provided are methods of using non-naturally occurring CKPs that bind to VEGF-A, Including diagnostic and therapeutic compositions and methods. Non-naturally CKPs that bind low density lipoprotein receptor-related protein 6 (LRP6) are also provided.

公开(公告)号：US10787484B2

公开(公告)日：2020-09-29

申请号：US16229226

申请日：2018-12-21

Applicant: Genentech, Inc.

Inventor： Maureen Beresini ,  Daniel Burdick ,  Charles Eigenbrot, Jr. ,  Daniel Kirchhofer ,  Robert Lazarus ,  Wei Li ,  John Quinn ,  Nicholas Skelton ,  Mark Ultsch ,  Yingnan Zhang

IPC: C07K7/06 ,  C07K7/02 ,  C12N9/64 ,  C12Q1/37 ,  G01N33/573 ,  G01N33/92 ,  C40B40/10 ,  C07K14/00 ,  A61K47/62 ,  A61P3/06 ,  A61K38/00

Abstract: The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

公开(公告)号：US20200299408A1

公开(公告)日：2020-09-24

申请号：US16790616

申请日：2020-02-13

Applicant: Genentech, Inc.

Inventor： Xiaocheng CHEN ,  Mark S. DENNIS ,  Allen J. EBENS, JR. ,  Teemu T. JUNTTILA ,  Robert F. KELLEY ,  Mary A. MATHIEU

IPC: C07K16/32 ,  C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  A61K45/06 ,  A61K31/573 ,  A61K47/68

Abstract: The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.

公开(公告)号：US10765312B2

公开(公告)日：2020-09-08

申请号：US15403656

申请日：2017-01-11

Applicant: GENENTECH, INC.

Inventor： Michael Bartlett ,  Yi-Zhong Wang

IPC: A61B3/00 ,  A61B3/032 ,  A61B3/11 ,  A61B3/12

Abstract: In an embodiment of the disclosure, there is provided a handheld vision tester for vision self-testing by a user. The handheld vision tester comprises a touchscreen display, a control, and an interface port. The touchscreen display is configured to present different shapes, either statically or dynamically, to the user for the vision self-testing. One of the different shapes may be a modulated version of another similar shape displayed at the same time and includes a modulated edge. The control is configured to allow a user to trigger operations of the tester and allow the user to select one of the different shapes. The handheld vision tester is configured to determine results of the vision self-testing from the user selections and store the results in the handheld vision tester. The interface port is configured to transmit the stored results to a healthcare provider who uses the results to enhance treatment routines.

公开(公告)号：US10759866B2

公开(公告)日：2020-09-01

申请号：US16240592

申请日：2019-01-04

Applicant: Genentech, Inc.

Inventor： Yung-Hsiang Kao ,  Michael W. Laird ,  Melody Trexler Schmidt ,  Rita L. Wong ,  Daniel P. Hewitt

IPC: C07K16/28 ,  C07K1/14 ,  A61K39/395

Abstract: Provide herein are methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.

公开(公告)号：US20200255512A1

公开(公告)日：2020-08-13

申请号：US16860891

申请日：2020-04-28

Applicant: Genentech, Inc.

Inventor： Germaine FUH ,  Chingwei V. LEE ,  Patrick KOENIG

IPC: C07K16/24 ,  C07K16/46 ,  A61K45/06 ,  A61K39/395

Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.

公开(公告)号：US20200254037A1

公开(公告)日：2020-08-13

申请号：US16637600

申请日：2018-08-06

Applicant: AMGEN INC. ,  GENENTECH, INC.

Inventor： Jennifer Lorraine Gansert ,  Sumita Shankar Bhatta ,  Joseph Paul Woodard, JR. ,  Edward Namserk Cha

IPC: A61K35/768 ,  A61K39/395 ,  A61K9/00 ,  A61P35/00

Abstract: Provided herein are methods of treating a subject with triple negative breast cancer or colorectal cancer. In exemplary embodiments, the method comprises administering to the subject a combination of an oncolytic virus, such as talimogene laherparepvec, and an anti-PD-L1 antibody, such as atezolizumab. In exemplary aspects, the oncolytic virus is administered to the subject at an initial dose followed by a second dose, wherein the initial dose is lower than the second dose. In exemplary aspects, the oncolytic virus is intrahepatically administered to the subject.